Dyne Therapeutics, Inc. Payments to Acquire Other Productive Assets
Dyne Therapeutics, Inc. (DYN) reported Payments to Acquire Other Productive Assets of $18.79 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherProductiveAssets · last filed 2026-03-02
- Dyne Therapeutics, Inc. payments to acquire other productive assets for the quarter ending 2025-12-31 was $0.00.
- Dyne Therapeutics, Inc. payments to acquire other productive assets for the quarter ending 2024-12-31 was $0.00.
- Dyne Therapeutics, Inc. payments to acquire other productive assets for fiscal 2025 was $18.79M.
- Dyne Therapeutics, Inc. payments to acquire other productive assets for fiscal 2024 was $0.00.
- Dyne Therapeutics, Inc. payments to acquire other productive assets for fiscal 2023 was $0.00.
| Period end | Payments to Acquire Other Productive Assets 3 month | Payments to Acquire Other Productive Assets 9 month | Payments to Acquire Other Productive Assets 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $18.79M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $18.79M 10-Q · filed 2025-11-05 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |